Search Result

Results for "

Hla

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CD74 (7) AIM2 (1) Akt (1) Amino Acid Derivatives (2) Antibiotic (7) Apoptosis (3) Bacterial (9) Biochemical Assay Reagents (1) C-type Lectin-like Receptors (CTLRs) (2) Calcium Channel (2) Cannabinoid Receptor (1) Cathepsin (1) CCR (1) CD28 (1) CD3 (2) CD47 (1) CMV (3) Complement System (1) DNA/RNA Synthesis (1) Drug Isomer (1) EBV (9) EGFR (2) Fluorescent Dye (1) Hapten (1) HCV (1) HIV (2) HPV (3) IFNAR (7) Influenza Virus (4) Insulin Receptor (2) Interleukin Related (5) Isotope-Labeled Compounds (1) JNK (1) LAG-3 (2) LILRB (2) MAP4K (1) Melanocortin Receptor (1) MHC (29) Orexin Receptor (OX Receptor) (1) Parasite (4) Reactive Oxygen Species (ROS) (2) Reference Standards (2) Ser/Thr Kinase (1) Small Interfering RNA (siRNA) (22) STING (1) Survivin (1) TNF Receptor (4) Toll-like Receptor (TLR) (2) Transmembrane Glycoprotein (4) TRP Channel (1) Tyrosinase (3)
By Research Areas:	Cancer (62) Cardiovascular Disease (1) Infection (23) Inflammation/Immunology (43) Metabolic Disease (2) Neurological Disease (3)
Oligonucleotides:	CpG ODNs (4) Human Pre-designed siRNA Sets (22) siRNAs (22)

117

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Inhibitory Antibodies

Natural
Products

224

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: CD74

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-161111

KVS0001	Ser/Thr Kinase	Cancer
KVS0001 is a selective SMG1 inhibitor. KVS0001 elevates the expression of transcripts and proteins resulting from truncating mutations. KVS0001 increased the presentation of immune-targetable HLA class I-associated peptides from nonsense-mediated decay (NMD)-downregulated proteins on the surface of cancer cells. KVS0001 exerts anti-tumor properties and can be studied in research for NMD-related diseases, including cancer and inherited diseases .

HY-P99339

Tebentafusp IMCgp100	Interleukin Related TNF Receptor	Cancer
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100*-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .

HY-P99573

Tebotelimab MGD-013	LAG-3	Inflammation/Immunology Cancer
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .

HY-N2245

Schisandrone	CD74	Cancer
Schisandrone, a 4-aryltetralone lignan, is isolated from the dried fruits of Schisandra sphenanthera . Schisandrone is an alpha-hemolysin (Hla) inhibitor that downregulates the transcript levels of hla, agrA and RNAIII. Hla is an integral virulence determinant in Staphylococcus aureus that determines pathogenicity. Schisandrone is a potent inhibitor against MRSA pneumonia .

HY-P1780

CEF20	CMV	Infection
CEF20 is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503).

HY-P5475

BMLF1 (280–288)	EBV	Others
BMLF1 (280–288) is a biological active peptide. (HLA A2.1-restricted epitope from Epstein-Barr Virus lytic protein BMLF1 (280-288).)

HY-P5470

LMP2A (426-434)	EBV IFNAR	Inflammation/Immunology
LMP2A (426-434) is a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). LMP2A (426-434) can trigger an immune response in individuals expressing different HLA-A02 subtypes (A02:01, A02:03, A02:06 and A02:07). LMP2A (426-434) can induce a strong IFN-γ* secretion response, stimulating the production of a high proportion of CD8 ⁺ IFN-γ ⁺ T cells. LMP2A (426-434) induces specific CTLs to effectively kill target cells expressing LMP2A. LMP2A (426-434) can be used to study EBV-related malignant tumors (such as Hodgkin's disease and nasopharyngeal carcinoma) .

HY-P1826

CLIP (86-100)	CD74	Inflammation/Immunology Cancer
CLIP (86-100) is amino acids 86 to 100 fragment of class II-associated invariant chain peptide (CLIP). CLIP is a small self-peptide and cleavage product of the invariant chain that resides in the HLA-II antigen binding groove and is believed to play a critical role in the assembly and transport of MHC class II alphabetaIi complexes through its interaction with the class II peptide-binding site .

HY-103333

Arvanil N-Vanillylarachidonamide	TRP Channel Cannabinoid Receptor CD74 Akt Orexin Receptor (OX Receptor)	Neurological Disease Inflammation/Immunology
Arvanil (N-Vanillylarachidonamide) is a mixed agonist of CB1 and TRPV1 receptors. Arvanil downregulates CD25, *HLA-DR, CD134/OX40, blocks G1/S phase transition, and induces phosphorylation of Akt*. Arvanil does not induce apoptosis in cells. Arvanil inhibits lymphocyte activation and ameliorates autoimmune encephalomyelitis. Arvanil can be used in research related to Huntington's disease, vomiting, and multiple sclerosis .

HY-P10493

NY-ESO-1 (157-165) peptide	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .

HY-P990189

*Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243)*	MHC Apoptosis Reactive Oxygen Species (ROS)	Infection Cancer
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to monkey/human MHC class II. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can inhibits tumor cells proliferation and induce apoptosis. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) increases cellular reactive oxygen species (ROS) and loss of mitochondrial membrane potential in human endothelial cells. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can be used for the researches of cancer and infection, such as lymphoma .

HY-P99551

Tosatoxumab KBSA301; AR-301	Antibiotic Bacterial	Infection
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992) .

HY-P1780A

CEF20 TFA	CMV	Infection
CEF20 TFA is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503).

HY-P3813

Tyrosinase (206-214), human	Tyrosinase	Inflammation/Immunology Cancer
Tyrosinase (206-214), human (AFLPWHRLF), a 9-amino acid peptide, is a tyrosinase epitope. Tyrosinase (206-214), human can be recognized by HLA-A24 restricted, tumor-infiltrating lymphocytes (TIL) .

HY-P1778A

HPV16 E7 (86-93) TFA	HPV	Infection
HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas .

HY-P5425A

Tetanus Toxin (830–844) TFA	Transmembrane Glycoprotein	Cancer
Tetanus Toxin (830–844) TFA is a biological active peptide. (tetanus toxin-derived peptide TT830–844 CD4 ⁺ T-cell epitope. This promiscuous CD4 ⁺ T-cell epitope can bind to a wide range of HLA–DRB molecules and is thus expected to activate CD4 ⁺ T-cell responses in a large part of the human population) .

HY-157269

J10-1	Hapten	Inflammation/Immunology
J10-1 is a hapten small molecule. J10-1 accelerates peptide exchange in MHC class II molecules in an HLA-DM-independent manner, and its effect is not affected by the polymorphism of the P1 pocket of MHC class II molecules. J10-1 enhances the processes of peptide dissociation, peptide binding and peptide association of MHC class II molecules on the surface of B cells. J10-1 can be used for research on immunoregulation .

HY-RS06217

HLA-G Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-G Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-G gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-G Human Pre-designed siRNA Set A HLA-G Human Pre-designed siRNA Set A

HY-P3742

Tyrosinase (192-200), human mouse	Tyrosinase MHC	Cancer
Tyrosinase (192-200), human mouse is a **HLA-B4403***-restricted tyrosinase epitope with affinity for *HLA-B4403* and *HLA-B4402. Tyrosinase (192-200), human mouse binds to *HLA-B4403* to form a complex, which is recognized by the autologous cytotoxic T lymphocyte clone 22/31 derived from melanoma. Tyrosinase (192-200), human mouse binds to HLA-B4402 to form a complex, which is recognized by the CTL clone 329B/5 derived from healthy HLA-B4402** donors. Tyrosinase (192-200), human mouse is applicable to melanoma-related research .

HY-P11084

WT1 126-134 peptide	MHC	Inflammation/Immunology Cancer
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (K_d = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .

HY-P10664

EBV EBNA3B (416-424)	EBV	Inflammation/Immunology
EBV EBNA3B (416-424) is an HLA-A11-restricted peptide antigen derived from EBV EBNA3B protein .

HY-P1919

[Asp371]-Tyrosinase (369-377), human	Tyrosinase	Cancer
Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy .

HY-P990714

Obertamig	CD3	Inflammation/Immunology
Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonal antibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv) .

HY-P5898

Z-Val-Val-Nle-diazomethylketone Z-Val-Val-Nle-CHN2	Cathepsin MHC	Inflammation/Immunology
Z-Val-Val-Nle-diazomethylketone is a cathepsin S (CATS) inhibitor. Z-Val-Val-Nle-diazomethylketone significantly inhibits the IFNg-induced upregulation of the MHCII molecules HLA-DR and Ii-p33/35 with an increase of Ii-p10 protein level. Z-Val-Val-Nle-diazomethylketone can be used for dermatological diseases like psoriasis, atopic dermatitis and actinic keratosis research .

HY-N7118

Clindamycin hydrochloride monohydrate	Bacterial Antibiotic	Infection Cancer
Clindamycin hydrochloride monohydrate is an oral protein synthesis inhibitory agent that has the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin hydrochloride monohydrate resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin hydrochloride monohydrate decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla) .

HY-150749A

ODN D-SL03 sodium	IFNAR	Cancer
ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .

HY-P10493A

NY-ESO-1 (157-165) peptide TFA	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .

HY-P991610

S-095029 Sym025	C-type Lectin-like Receptors (CTLRs)	Cancer
S-095029 is a humanized IgG1 monoclonal antibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .

HY-173526

H052	Bacterial Calcium Channel	Infection
H052 is a selective Staphylococcus aureus α-hemolysin (Hla) inhibitor. H052 binds to Hla monomers, disrupts the interaction with host cell membranes to block pore formation, inhibiting calcium ion influx, cytotoxicity, and inflammatory responses. H052 exhibits potency (EC₅₀=30 nM in U937 cells) against Hla-induced calcium influx. H052 is promising for research of lung infections caused by S. aureus .

HY-P991750

*Anti-pan MHC Class II (HLA* II) Antibody (IVA12)**	MHC	Inflammation/Immunology
Anti-pan MHC Class II (HLA II) Antibody (IVA12) recognizes human HLA-II (HLA-DR, HLA-DP, and HLA-DQ). Anti-pan MHC Class II (HLA II) Antibody (IVA12) blocks MHC-II in vitro. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .

HY-P10593

*Influenza A NP (383-391) (HLA-B27)*	Transmembrane Glycoprotein Influenza Virus	Cancer
Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research .

HY-P1700

BCMA72-80	TNF Receptor	Cancer
BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with great affinity to HLA-A2, used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors .

HY-P1881

HPV16-E711-20 epitope	HPV	Cancer
HPV16-E711-20 epitope is a well-known HLA-A ^0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro*. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .

HY-P11379

ELTLGEFLKL	Survivin MHC	Inflammation/Immunology Cancer
ELTLGEFLKL is a survivin peptide. ELTLGEFLKL shows significant stabilization of **HLA-A0201***. ELTLGEFLKL can be used in the research of tumor immunotherapy .

HY-P990061

Polzastobart JTX 8064	LILRB Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .

HY-P1757

HIV p17 Gag (77-85)	HIV	Infection
HIV p17 Gag (77-85) is an HLA-A*0201(A2)-restricted CTL epitope, used in the research of anti-HIV .

HY-P1890

CEF14, EBV Rta Protein (28-37)	EBV	Infection
CEF14, EBV Rta Protein (28-37) is the HLA A24-restricted epitope from Epstein-Barr Virus Rta protein (28-37).

HY-P11340

VMAPRTLFL	MHC	Infection Inflammation/Immunology
VMAPRTLFL is a 9-mer peptide derived from the signal peptide of HLA-G and can serve as a peptide ligand for *HLA-E. VMAPRTLFL plays a crucial role in regulating the functions of adaptive natural killer (NK) cells. Specifically, VMAPRTLFL enriches FcεRγ ^- adaptive NK cells, upregulates the expression of CD25, and enhances their proliferative activity, antibody-dependent cellular cytotoxicity (ADCC), and IFN-γ* release. VMAPRTLFL can be used in research related to human cytomegalovirus (HCMV) infection, transplant rejection, and pregnancy immunity .

HY-P11090

TpD	MHC	Inflammation/Immunology
TpD is a chimeric T-helper epitope. TpD has a special site that cathepsin can cut. Immunization with TpD produces a strong antibody response. TpD promotes long-term CD4 immune responses in animals and humans. TpD binds well to many human MHC class II types, mainly *HLA-DRB1. It also binds some other HLA* alleles like DRB3, DRB4, DRB5, DP, and DQ. TpD can be used to improve the immune response of peptide vaccines .

HY-P1778

HPV16 E7 (86-93)	HPV	Infection
HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas .

HY-106156

Allotrap 07	MHC	Cardiovascular Disease Inflammation/Immunology
Allotrap 07 is a synthetic peptide composed of residues 75-84 of HLA-B7, a class I MHC molecule. Allotrap 07 combined with Cyclosporin A (HY-B0579) induces donor-specific tolerance in rat cardiac allografts, significantly prolonging graft survival .

HY-P3248

J5 peptide Myelin basic protein (85-99) antagonist	Biochemical Assay Reagents	Inflammation/Immunology
J5 peptide is an MBP inhibitor that competitively inhibits the binding of MBP_85-99 to *HLA-DR2*. J5 peptide alleviates PLP_139-151/MBP_85-99-induced experimental autoimmune encephalomyelitis (EAE) in mice. J5 peptide can be used in research on inflammatory and immune diseases .

HY-P11089

TP53 neoepitope	MHC	Cancer
TP53 neoepitope is a high-affinity antigenic peptide targeting *HLA-A*. TP53 neoepitope can triggers CD8 ⁺ T cell-mediated killing of TP53-mutant tumor cells. TP53 neoepitope is promising for research of solid tumors harboring TP53 hotspot mutations (e.g., R175H, R273H) .

HY-P4032

HCV Peptide (35-44)	HCV	Inflammation/Immunology
HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .

HY-159123

KHK-6	MAP4K	Cancer
KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC₅₀ of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ T cells, and enhances T cell-mediated killing activity of SKOV3 and A549 cells .

HY-P10662

HLA-B*0801-binding EBV peptide	MHC	Infection Inflammation/Immunology
HLA-B0801-binding EBV peptide is an Epstein-Barr virus (EBV) epitope FLRGRAYGL. HLA-B0801-binding EBV peptide can bind to the HLA-B0801 molecule. HLA-B0801-binding EBV peptide can be presented to CD8+ T cells through HLA-B*0801 to activate a specific immune response .

HY-RS06196

HLA-A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-A Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-A Human Pre-designed siRNA Set A HLA-A Human Pre-designed siRNA Set A

HY-RS06200

HLA-DMB Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DMB Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DMB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DMB Human Pre-designed siRNA Set A HLA-DMB Human Pre-designed siRNA Set A

HY-RS06216

HLA-F Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-F Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-F gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-F Human Pre-designed siRNA Set A HLA-F Human Pre-designed siRNA Set A

Cat. No.	Product Name	Type

HY-D3334

PE-CF594

Fluorescent Dyes

PE-CF594 is a labeled monoclonal antibody conjugate that specifically binds to HLA-DR on the surface of monocytes and B cells, while acting as a signal attenuator. Through steric hindrance and a possible fluorescence resonance energy transfer mechanism, PE-CF594 specifically reduces the fluorescence intensity of PE-CD124 staining, but does not interfere with the staining of other PE-labeled antibodies such as CD40, CD4 or CD14. PE-CF594 can also be used to detect the emission signal of mt-Keima after excitation with a 561-nm laser, thereby effectively evaluating mitophagy activity .

Cat. No.	Product Name	Target	Research Area

HY-P1745

InsB (9-23) Insulin B chain (9-23)	MHC Insulin Receptor IFNAR	Inflammation/Immunology
InsB (9-23) (Insulin B chain (9-23)) is an *HLA-DQ8*-restricted insulin B-chain peptide composed of amino acid residues 9-23. InsB (9-23) serves as a major MHC II class-restricted antigen. InsB (9-23) supports the recognition and activation of T cells, stimulates the secretion of IFN-γ and cytokines, and induces cross-reactive immune responses. InsB (9-23)-specific CD4 T cells can initiate diabetes . InsB (9-23) can be used in research related to type 1 diabetes and autoimmune diabetes .

HY-P11303

PADRE peptide	CD74 MHC	Neurological Disease Cancer
PADRE peptide is a pan-HLA-DR binding epitope and immunostimulant. PADRE peptide binds to the peptide-binding groove of MHC class II molecules for presentation to CD4 ⁺ T cells, thereby effectively stimulating specific immune responses. PADRE peptide not only enhances anti-tumor immune responses, inhibits tumor growth and prolongs survival; it also significantly increases the frequency of E7-specific CD8 ⁺ T cells and improves therapeutic efficacy against TC-1 tumors when used in combination with E7 peptide-based vaccines and poly (I:C). The intensity of the immune response induced by PADRE peptide is lower than that of the Ii-PADRE DNA vaccine, and it fails to enhance the immune effect of CRT-E7 DNA. PADRE peptide is widely applicable to research on related tumors such as melanoma, glioblastoma and cervical cancer .

HY-P0277

Carcinoembryonic antigen peptide 1 CEA peptide	Peptides	Cancer
Carcinoembryonic antigen peptide 1 (CEA peptide) is a carcinoembryonic antigen (CEA)-derived peptide. Carcinoembryonic antigen peptide 1 is a potential HLA-A*0201-restricted CTL epitope that can be used for the study of CTL-mediated epithelial-derived cancers .

HY-P1780

CEF20	CMV	Infection
CEF20 is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503).

HY-P5475

BMLF1 (280–288)	EBV	Others
BMLF1 (280–288) is a biological active peptide. (HLA A2.1-restricted epitope from Epstein-Barr Virus lytic protein BMLF1 (280-288).)

HY-P5470

LMP2A (426-434)	EBV IFNAR	Inflammation/Immunology
LMP2A (426-434) is a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). LMP2A (426-434) can trigger an immune response in individuals expressing different HLA-A02 subtypes (A02:01, A02:03, A02:06 and A02:07). LMP2A (426-434) can induce a strong IFN-γ* secretion response, stimulating the production of a high proportion of CD8 ⁺ IFN-γ ⁺ T cells. LMP2A (426-434) induces specific CTLs to effectively kill target cells expressing LMP2A. LMP2A (426-434) can be used to study EBV-related malignant tumors (such as Hodgkin's disease and nasopharyngeal carcinoma) .

HY-P1826

CLIP (86-100)	CD74	Inflammation/Immunology Cancer
CLIP (86-100) is amino acids 86 to 100 fragment of class II-associated invariant chain peptide (CLIP). CLIP is a small self-peptide and cleavage product of the invariant chain that resides in the HLA-II antigen binding groove and is believed to play a critical role in the assembly and transport of MHC class II alphabetaIi complexes through its interaction with the class II peptide-binding site .

HY-P10493

NY-ESO-1 (157-165) peptide	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .

HY-P1780A

CEF20 TFA	CMV	Infection
CEF20 TFA is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503).

HY-P3813

Tyrosinase (206-214), human	Tyrosinase	Inflammation/Immunology Cancer
Tyrosinase (206-214), human (AFLPWHRLF), a 9-amino acid peptide, is a tyrosinase epitope. Tyrosinase (206-214), human can be recognized by HLA-A24 restricted, tumor-infiltrating lymphocytes (TIL) .

HY-P1778A

HPV16 E7 (86-93) TFA	HPV	Infection
HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas .

HY-P5425A

Tetanus Toxin (830–844) TFA	Transmembrane Glycoprotein	Cancer
Tetanus Toxin (830–844) TFA is a biological active peptide. (tetanus toxin-derived peptide TT830–844 CD4 ⁺ T-cell epitope. This promiscuous CD4 ⁺ T-cell epitope can bind to a wide range of HLA–DRB molecules and is thus expected to activate CD4 ⁺ T-cell responses in a large part of the human population) .

HY-P3742

Tyrosinase (192-200), human mouse	Tyrosinase MHC	Cancer
Tyrosinase (192-200), human mouse is a **HLA-B4403***-restricted tyrosinase epitope with affinity for *HLA-B4403* and *HLA-B4402. Tyrosinase (192-200), human mouse binds to *HLA-B4403* to form a complex, which is recognized by the autologous cytotoxic T lymphocyte clone 22/31 derived from melanoma. Tyrosinase (192-200), human mouse binds to HLA-B4402 to form a complex, which is recognized by the CTL clone 329B/5 derived from healthy HLA-B4402** donors. Tyrosinase (192-200), human mouse is applicable to melanoma-related research .

HY-P11084

WT1 126-134 peptide	MHC	Inflammation/Immunology Cancer
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (K_d = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .

HY-P10664

EBV EBNA3B (416-424)	EBV	Inflammation/Immunology
EBV EBNA3B (416-424) is an HLA-A11-restricted peptide antigen derived from EBV EBNA3B protein .

HY-P1919

[Asp371]-Tyrosinase (369-377), human	Tyrosinase	Cancer
Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy .

HY-P5898

Z-Val-Val-Nle-diazomethylketone Z-Val-Val-Nle-CHN2	Cathepsin MHC	Inflammation/Immunology
Z-Val-Val-Nle-diazomethylketone is a cathepsin S (CATS) inhibitor. Z-Val-Val-Nle-diazomethylketone significantly inhibits the IFNg-induced upregulation of the MHCII molecules HLA-DR and Ii-p33/35 with an increase of Ii-p10 protein level. Z-Val-Val-Nle-diazomethylketone can be used for dermatological diseases like psoriasis, atopic dermatitis and actinic keratosis research .

HY-P3640

MAGE-3 Antigen (167-176) (human)	Peptides	Cancer
MAGE-3 Antigen (167-176) (human) is a polypeptide containing eight amino acids. MAGE-3 Antigen (167-176) (human) is a human leukocyte antigen HLA-B44 molecules epitope encoded by melanoma antigen gene (MAGE) .

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .

HY-P5425

Tetanus Toxin (830–844)	Peptides	Others
Tetanus Toxin (830–844) is a biological active peptide. (tetanus toxin-derived peptide TT830–844 CD4+ T-cell epitope. This promiscuous CD4+ T-cell epitope can bind to a wide range of HLA–DRB molecules and is thus expected to activate CD4+ T-cell responses in a large part of the human population)

HY-P10493A

NY-ESO-1 (157-165) peptide TFA	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .

HY-P10994

Eps8 peptide 327 Eps8(327-335)	EGFR IFNAR Interleukin Related TNF Receptor Complement System Apoptosis	Inflammation/Immunology Cancer
Eps8 peptide 327 is an HLA-A2402-restricted peptide antigen derived from Eps8 protein. Eps8 peptide 327 has potent antitumor activity with significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cells proliferation, induces apoptosis* and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. Eps8 peptide 327 significantly inhibits tumor growth in HT-29 xenograft mcie models .

HY-P10593

*Influenza A NP (383-391) (HLA-B27)*	Transmembrane Glycoprotein Influenza Virus	Cancer
Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research .

HY-P1700

BCMA72-80	TNF Receptor	Cancer
BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with great affinity to HLA-A2, used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors .

HY-P1881

HPV16-E711-20 epitope	HPV	Cancer
HPV16-E711-20 epitope is a well-known HLA-A ^0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro*. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .

HY-P11379

ELTLGEFLKL	Survivin MHC	Inflammation/Immunology Cancer
ELTLGEFLKL is a survivin peptide. ELTLGEFLKL shows significant stabilization of **HLA-A0201***. ELTLGEFLKL can be used in the research of tumor immunotherapy .

HY-P1757

HIV p17 Gag (77-85)	HIV	Infection
HIV p17 Gag (77-85) is an HLA-A*0201(A2)-restricted CTL epitope, used in the research of anti-HIV .

HY-P1890

CEF14, EBV Rta Protein (28-37)	EBV	Infection
CEF14, EBV Rta Protein (28-37) is the HLA A24-restricted epitope from Epstein-Barr Virus Rta protein (28-37).

HY-P11340

VMAPRTLFL	MHC	Infection Inflammation/Immunology
VMAPRTLFL is a 9-mer peptide derived from the signal peptide of HLA-G and can serve as a peptide ligand for *HLA-E. VMAPRTLFL plays a crucial role in regulating the functions of adaptive natural killer (NK) cells. Specifically, VMAPRTLFL enriches FcεRγ ^- adaptive NK cells, upregulates the expression of CD25, and enhances their proliferative activity, antibody-dependent cellular cytotoxicity (ADCC), and IFN-γ* release. VMAPRTLFL can be used in research related to human cytomegalovirus (HCMV) infection, transplant rejection, and pregnancy immunity .

HY-P11090

TpD	MHC	Inflammation/Immunology
TpD is a chimeric T-helper epitope. TpD has a special site that cathepsin can cut. Immunization with TpD produces a strong antibody response. TpD promotes long-term CD4 immune responses in animals and humans. TpD binds well to many human MHC class II types, mainly *HLA-DRB1. It also binds some other HLA* alleles like DRB3, DRB4, DRB5, DP, and DQ. TpD can be used to improve the immune response of peptide vaccines .

HY-P1778

HPV16 E7 (86-93)	HPV	Infection
HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas .

HY-106156

Allotrap 07	MHC	Cardiovascular Disease Inflammation/Immunology
Allotrap 07 is a synthetic peptide composed of residues 75-84 of HLA-B7, a class I MHC molecule. Allotrap 07 combined with Cyclosporin A (HY-B0579) induces donor-specific tolerance in rat cardiac allografts, significantly prolonging graft survival .

HY-P3248

J5 peptide Myelin basic protein (85-99) antagonist	Biochemical Assay Reagents	Inflammation/Immunology
J5 peptide is an MBP inhibitor that competitively inhibits the binding of MBP_85-99 to *HLA-DR2*. J5 peptide alleviates PLP_139-151/MBP_85-99-induced experimental autoimmune encephalomyelitis (EAE) in mice. J5 peptide can be used in research on inflammatory and immune diseases .

HY-P11089

TP53 neoepitope	MHC	Cancer
TP53 neoepitope is a high-affinity antigenic peptide targeting *HLA-A*. TP53 neoepitope can triggers CD8 ⁺ T cell-mediated killing of TP53-mutant tumor cells. TP53 neoepitope is promising for research of solid tumors harboring TP53 hotspot mutations (e.g., R175H, R273H) .

HY-P4032

HCV Peptide (35-44)	HCV	Inflammation/Immunology
HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .

HY-P10835

LAG-3 cyclic peptide inhibitor C25	LAG-3	Cancer
LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a K_d value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with *HLA-DR* (MHC-II) and activate CD8 ⁺ T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .

HY-P10662

HLA-B*0801-binding EBV peptide	MHC	Infection Inflammation/Immunology
HLA-B0801-binding EBV peptide is an Epstein-Barr virus (EBV) epitope FLRGRAYGL. HLA-B0801-binding EBV peptide can bind to the HLA-B0801 molecule. HLA-B0801-binding EBV peptide can be presented to CD8+ T cells through HLA-B*0801 to activate a specific immune response .

HY-P2507

NY-ESO-1 (87-111)	Peptides	Cancer
NY-ESO-1 (87-111) is a pan-MHC class II-restricted peptide sequence. NY-ESO-1 (87-111) binds to multiple HLA-DR and HLA-DP4 molecules, and stimulates Th1-type and Th-2/Th0-type CD4 ⁺ T cells when presented in the context of HLA-DR and HLA-DP4 molecules .

HY-P5294

YLLEMLWRL	EBV	Cancer
YLLEMLWRL is an HLA-A2-restricted T cell epitope sequence corresponding to codon 125-133. Among them, YLLEMLWRL sequence is the main mutation site of HLA-A2-restricted CTL epitope sequence .

HY-P10339

SMCY peptide	Peptides	Inflammation/Immunology
SMCY peptide inhibits the binding of iodinated standard peptide to *HLA-B7* with an IC₅₀ of 34 nM. As an epitope of the H-Y antigen, SMCY peptide can be presented by the HLA-B7 molecule and recognized by specific T cells, leading to transplant rejection .

HY-P4628

TPNQRQNVC LRH-1 peptide	Peptides	Inflammation/Immunology
TPNQRQNVC is a nonapeptide and is the epitope of HLA-B0702. TPNQRQNVC induces a CD8+ T cell immune response .

HY-P11179

VTEHDTLLY	CMV	Infection Inflammation/Immunology
VTEHDTLLY is a HLA class I-restricted CMV peptide epitope. VTEHDTLLY can be used in the research of CMV-specific T cell expansion .

HY-P5476

Influenza virus NP (44-52)	Peptides	Others
Influenza virus NP (44-52) is a biological active peptide. (HLA-A*01 restricted epitope from influenza virus nucleoprotein (44-52).)

HY-P1842

MAGE-A3 (195-203)	Peptides	Cancer
MAGE-A3 (195-203) is a human leukocyte antigen (HLA) -A24 molecules epitope encoded by melanoma antigen gene (MAGE) .

HY-106187

MART-1 (27-35) (human)	Peptides	Inflammation/Immunology
MART-1 (27-35) (human) is an immunogenic epitope recognized by HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TIL) .

HY-P5478

Influenza virus PA (46-54)	DNA/RNA Synthesis Influenza Virus	Others
Influenza virus PA (46-54) is a biological active peptide. (HLA-A*0201 restricted epitope from influenza virus RNA polymerase subunit, PA (46-54).)

HY-P10663

EBV EBNA3A (379-387)	EBV	Infection Inflammation/Immunology
EBV EBNA3A (379-387) is an antigenic epitope that may elicit the latent-specific CD8 ⁺ T cell response in HLA-B*07:02 ⁺ individuals .

HY-P5482

Epstein-barr virus BRLF1 (134-142)	EBV	Others
Epstein-barr virus BRLF1 (134-142) is a biological active peptide. (HLA-A11 restricted epitope from Epstein-Barr Virus BRLF1 (134-142).)

HY-P1901

Insulin alpha-chain (1-13)	Insulin Receptor	Metabolic Disease
Insulin alpha-chain (1-13) is a human leucocyte antigen (HLA)-DR4-restricted epitope comprising the first 13 amino acids of the insulin A-chain .

HY-P1857

CEF7, Influenza Virus NP (380-388)	Influenza Virus	Infection
CEF7, Influenza Virus NP (380-388) is a HLA-B ^*08 restricted influenza virus nucleoprotein epitope. Influenza virus NP functions as a key adapter molecule between virus and host cell processes .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99339

Tebentafusp IMCgp100	Interleukin Related TNF Receptor	Cancer
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100*-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .

HY-P99573

Tebotelimab MGD-013	LAG-3	Inflammation/Immunology Cancer
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .

HY-P990189

*Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243)*	MHC Apoptosis Reactive Oxygen Species (ROS)	Infection Cancer
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to monkey/human MHC class II. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can inhibits tumor cells proliferation and induce apoptosis. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) increases cellular reactive oxygen species (ROS) and loss of mitochondrial membrane potential in human endothelial cells. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can be used for the researches of cancer and infection, such as lymphoma .

HY-P99551

Tosatoxumab KBSA301; AR-301	Antibiotic Bacterial	Infection
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992) .

HY-P990832

Anti-MHC Class I Antibody (W6/32)	MHC	Inflammation/Immunology
Anti-MHC Class I Antibody (W6/32) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human MHC Class I. Anti-MHC Class I Antibody (W6/32) reacts with the human major histocompatibility complex (MHC) class I, HLA-A, B, and C. Anti-MHC Class I Antibody (W6/32) increases adherence of monocytes to human endothelial cells. Anti-MHC Class I Antibody (W6/32) can be used for the research of immunology .

HY-P991230

MK-4830	Inhibitory Antibodies	Cancer
MK-4830 is a fully humanized monoclonal antibody of the immunoglobulin G4 subclass that specifically binds to ILT4 and blocks its interaction with HLA-G and other ligands. MK-4830 inhibits tumor growth in humanized mouse cancer models .

HY-P990714

Obertamig	CD3	Inflammation/Immunology
Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonal antibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv) .

HY-P991248

TTX-080	Inhibitory Antibodies	Cancer
TTX-080 is a humanized monoclonal antagonistic antibody targeting human leukocyte antigen G (HLA-G). TTX-080 exerts anti-tumor activity by relieving HLA-G-mediated immune suppression. TTX-080 is promising for research of solid tumors such as metastatic colorectal cancer (mCRC) and head and neck squamous cell carcinoma (mHNSCC) .

HY-P991610

S-095029 Sym025	C-type Lectin-like Receptors (CTLRs)	Cancer
S-095029 is a humanized IgG1 monoclonal antibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .

HY-P991750

*Anti-pan MHC Class II (HLA* II) Antibody (IVA12)**	MHC	Inflammation/Immunology
Anti-pan MHC Class II (HLA II) Antibody (IVA12) recognizes human HLA-II (HLA-DR, HLA-DP, and HLA-DQ). Anti-pan MHC Class II (HLA II) Antibody (IVA12) blocks MHC-II in vitro. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .

HY-P990061

Polzastobart JTX 8064	LILRB Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .

HY-P991247

*Anti-HLA-A2 (Hu8F4)*	MHC	Cancer
Anti-HLA-A2 (Hu8F4) is a human monoclonal antibody (mAb) targeting *HLA-A2. Anti-HLA*-A2 (Hu8F4) can be used in Acute myeloid leukaemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991366

IBI-397 AL008	CD47	Cancer
IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research .

HY-P991590

1D09C3	MHC Apoptosis JNK Reactive Oxygen Species (ROS)	Cancer
1D09C3 is a fully human anti-HLA-DR monoclonal antibody. 1D09C3 induces apoptosis and cell death involving a cascade of events, including ROS generation, JNK activation, mitochondrial membrane depolarization, and AIF release from mitochondria. 1D09C3 shows potent anti-tumor activity and increases overall survival and median survival in JVM-2 cells and GRANTA-519 cells xenograft mice models. 1D09C3 can be used for the researches of cancer, such as chronic lymphocytic leukemia (CLL) .

HY-P992018

*Anti-HLA-G Antibody*	MHC	Inflammation/Immunology
Anti-HLA-G Antibody is an anti-HLA-G antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P992017

*Anti-HLA-C Antibody*	MHC	Inflammation/Immunology
Anti-HLA-C Antibody is an anti-HLA-C antibody. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P991844

*Anti-HLA-DQ Antibody (1a3)*	CD74	Inflammation/Immunology
Anti-HLA-DQ Antibody (1a3) reacts with human HLA-DQ. HLA-DQ (DQ) is a cell surface receptor protein found on antigen-presenting cells. Recommend Isotype Controls: Mouse IgG2a kappa, Isotype Control (HY-P99978) .

HY-P991787

*Anti-HLA-A2 Antibody (BB7.2)*	MHC	Inflammation/Immunology
Anti-HLA-A2 Antibody (BB7.2) reacts with the alpha subunit of the human leukocyte antigen-A2 (HLA-A2). Recommend Isotype Controls: Mouse IgG2b kappa, Isotype Control (HY-P99982) .

HY-P991837

*Anti-HLA-DP Antibody (B7/21)*	CD74	Inflammation/Immunology
Anti-HLA-DP Antibody (B7/21) reacts with the class II major histocompatibility complex (MHC) antigen. Anti-HLA-DP Antibody (B7/21) recognizes a monomorphic determinant present on cells expressing DP1, DP2, DP3, DP4 and DP5. Recommend Isotype Controls: Mouse IgG3 kappa, Isotype Control (HY-P99985) .

HY-P992111

Elfritatug UCB4594	MHC	Cancer
Elfritatug (UCB4594) is a humanized monoclonal antibody targeting human leukocyte antigen-G (HLA-G). By binding to HLA-G on the surface of tumor cells, Elfritatug blocks its immunosuppressive effect, thereby enhancing the body's immune response against tumors .

HY-P992377

HY-0102	C-type Lectin-like Receptors (CTLRs)	Cancer
HY-0102 is a humanized IgG anti-NKG2A monoclonal antibody and immune checkpoint inhibitor targeting the *NKG2A/HLA-E* axis. HY-0102 is applicable for the research of advanced solid tumors .

HY-P990606

IMMU-114 IMMU-140 antibody	Inhibitory Antibodies	Inflammation/Immunology
IMMU-114 is a CHO expressed humanized antibody that targets *HLA-DR*. IMMU-114 is composed of huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.1 kDa. The isotype control for IMMU-114 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P992388

IO-108	LILRB	Cancer
IO-108 is a humanized IgG4 monoclonal antibody and a competitive inhibitor of LILRB2, with a K_D value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P0277

Carcinoembryonic antigen peptide 1 CEA peptide	Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Others
Carcinoembryonic antigen peptide 1 (CEA peptide) is a carcinoembryonic antigen (CEA)-derived peptide. Carcinoembryonic antigen peptide 1 is a potential HLA-A*0201-restricted CTL epitope that can be used for the study of CTL-mediated epithelial-derived cancers .

HY-N2245

Schisandrone	Monophenols Classification of Application Fields Lignans Phenols Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill. Disease Research Fields Source Classification Cancer	CD74
Schisandrone, a 4-aryltetralone lignan, is isolated from the dried fruits of Schisandra sphenanthera . Schisandrone is an alpha-hemolysin (Hla) inhibitor that downregulates the transcript levels of hla, agrA and RNAIII. Hla is an integral virulence determinant in Staphylococcus aureus that determines pathogenicity. Schisandrone is a potent inhibitor against MRSA pneumonia .

HY-N10116A

Calamenene	Cupressaceae Cupressus L. Plants Source Classification	Interleukin Related IFNAR Calcium Channel Bacterial CCR
Calamenene is a sesquiterpene compound . Calamenene promotes dendritic cell maturation, upregulates CD1a, CD80, CD83, CD86, *HLA-DR* and CCR7 on the cell surface, reduces endocytic activity, enhances T cell-stimulating capacity, drives Th1 polarization through the secretion of IL-12, induces IFN-γ production, decreases IL-4 generation, and triggers intracellular Ca ²⁺ mobilization as well as dendritic cell migration towards MIP-3β. Calamenene exerts bacteriostatic and bactericidal growth-inhibitory effects against pathogenic Vibrio harveyi. Calamenene can be used in studies related to cancer and bacterial infections .

Cat. No.	Product Name	Chemical Structure

HY-B1455S1

Clindamycin-13C,d3

Clindamycin- ¹³C,d₃ is the ¹³C- and deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .

HY-B1455S

Clindamycin-d3 hydrochloride

Clindamycin-d₃ (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .

Host:	Mouse (24) Rabbit (25)
Reactivity:	Human (49) mouse (1) Mouse (7) Rat (10)
Application:	IHC-P (33) ICC/IF (17) mIHC (1) IF-Tissue (2) IP (12) WB (33) FC (26) WB ICC/IF (1) ELISA (21)
Isotype:	IgG2a,IgG/Kappa (1) IgG (24) IgG1 (12) IgG/Kappa (1) IgG2a (2) IgG2b (6)
Conjugation:	Non-conjugated (49) Biotin (125)
Clonality:	Monoclonal (31) Monoclonal Antibody (1) Recombinant (18)
Modification:	Unmodified (33)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83945

	HLA-DPB1 Antibody (YA3642) DPB1; Hla-DP; Hla-DPB; Hla-DP1B	IHC-P, FC, ELISA	Human, Rat
	HLA-DPB1 Antibody (YA3642) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HLA-DPB1.

HY-P88573

	HLA Antibody (YA8257) Hla-DRB	IHC-P	Human
	HLA Antibody (YA8257) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HLA.

HY-P83480

	HLA G Antibody (YA3225) Hla G antigen; MHC class I antigen G; Hla-G; Hla60; HlaG	WB	Human
	HLA G Antibody (YA3225) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA G.

HY-P83945A

	HLA-DPB1 Antibody (YA3642)(PBS only) DPB1; Hla-DP; Hla-DPB; Hla-DP1B	IHC-P, FC, ELISA	Human, Rat
	HLA-DPB1 Antibody (YA3642) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HLA-DPB1.

HY-P84246

	HLA-F Antibody (YA3943) HlaF; CDA12; Hla-5.4; Hla-CDA12	WB, FC, ELISA	Human, Mouse, Rat
	HLA-F Antibody (YA3943) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to HLA-F.

HY-P82867

	HLA-B Antibody (YA2612) Hla B; HlaB	WB, IHC-P	Human
	HLA-B Antibody (YA2612) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA-B.

HY-P88573A

	HLA Antibody (YA8257)(PBS only) Hla-DRB	IHC-P	Human
	HLA Antibody (YA8257) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HLA.

HY-P83917

	HLA-DRB1 Antibody (YA3614) SS1; DRB1; Hla-DRB; Hla-DR1B	WB, IHC-P, FC, ELISA	Human
	HLA-DRB1 Antibody (YA3614) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HLA-DRB1.

HY-P84246A

	HLA-F Antibody (YA3943)(PBS only) HlaF; CDA12; Hla-5.4; Hla-CDA12	WB, FC, ELISA	Human, Mouse, Rat
	HLA-F Antibody (YA3943) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to HLA-F.

HY-P83916

	HLA-DR Antibody (YA3613) MLRW; Hla-DRA1	WB, ICC/IF, FC, ELISA	Human
	HLA-DR Antibody (YA3613) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to HLA-DR.

HY-P83917A

	HLA-DRB1 Antibody (YA3614)(PBS only) SS1; DRB1; Hla-DRB; Hla-DR1B	WB, IHC-P, FC, ELISA	Human
	HLA-DRB1 Antibody (YA3614) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HLA-DRB1.

HY-P84161

	HLA-DPA1 Antibody (YA3858) DPA1; PLT1; HlaDP; HlaSB; DP(W3); DP(W4); Hla-DPA; Hla-DP1A; Hla-DPB1	WB, IHC-P, FC, ELISA	Human
	HLA-DPA1 Antibody (YA3858) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to HLA-DPA1.

HY-P84162

	HLA-DPA1 Antibody (YA3859) DPA1; PLT1; HlaDP; HlaSB; DP(W3); DP(W4); Hla-DPA; Hla-DP1A; Hla-DPB1	IHC-P, FC, ELISA	Human, Rat
	HLA-DPA1 Antibody (YA3859) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to HLA-DPA1.

HY-P83916A

	HLA-DR Antibody (YA3613)(PBS only) MLRW; Hla-DRA1	WB, ICC/IF, FC, ELISA	Human
	HLA-DR Antibody (YA3613) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to HLA-DR.

HY-P84161A

	HLA-DPA1 Antibody (YA3858)(PBS only) DPA1; PLT1; HlaDP; HlaSB; DP(W3); DP(W4); Hla-DPA; Hla-DP1A; Hla-DPB1	WB, IHC-P, FC, ELISA	Human
	HLA-DPA1 Antibody (YA3858) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to HLA-DPA1.

HY-P84162A

	HLA-DPA1 Antibody (YA3859)(PBS only) DPA1; PLT1; HlaDP; HlaSB; DP(W3); DP(W4); Hla-DPA; Hla-DP1A; Hla-DPB1	IHC-P, FC, ELISA	Human, Rat
	HLA-DPA1 Antibody (YA3859) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to HLA-DPA1.

HY-P83339

	HLA-DR Antibody (YA3084) 1 Publications Verification MLRW; Hla-DRA1; MHC class II antigen DRA; Hla class II histocompatibility antigen; DR alpha chain	WB, IHC-P, ICC/IF, FC	Human
	HLA-DR Antibody (YA3084) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA-DR.

HY-P81742

	HLA-DRB1 Antibody (YA1487) Hla-Drb1; DW2.2/DR2.2	WB, IHC-P, ICC/IF	Human
	HLA-DRB1 Antibody (YA1487) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA-DRB1.

HY-P86487

	HLA-DR Antibody (YA6179)	WB, IHC-P, ICC/IF, IP, ELISA	Human, Rat
	HLA-DR Antibody (YA6179) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA-DR.

HY-P83195

	HLA Class 1 A Antibody (YA2940) Aw-68; Hla class I histocompatibility antigen; A-28 alpha chain; MHC class I antigen A68; Hla-A; MHC class I antigen Hla* A heavy chain	WB, IHC-P, ICC/IF, IP, FC	Human
	HLA Class 1 A Antibody (YA2940) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA Class 1 A.

HY-P89408

	HLA-DQA1 Antibody (YA8856) Hla-DQA1; CD; CELIAC1; DQ-A1; GSE; Hla-DQA; DQ alpha 1 chain; DC-1 alpha chain; DC-alpha; Hla-DCA; MHC class II DQA1	WB, IHC-P, ICC/IF, IP, FC, IF-Tissue, mIHC	Human, Mouse, Rat
	HLA-DQA1 Antibody (YA8856) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA-DQA1.

HY-P82688

	HLA-DQA1 Antibody (YA2433) Hla-DQA1; CD; CELIAC1; DQ-A1; GSE; Hla-DQA; DQ alpha 1 chain; DC-1 alpha chain; DC-alpha; Hla-DCA; MHC class II DQA1	WB, IHC-P, IP	Human, Mouse, Rat
	HLA-DQA1 Antibody (YA2433) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA-DQA1.

HY-P810464

	HLA G Antibody (YA9763) Hla-G, Major Histocompatibility Complex, Class I, G, Hla Class I Histocompatibility Antigen, Alpha Chain G, Hla-G Histocompatibility Antigen, Class I, G, MHC Class I Antigen G, B2 Microglobulin, Hla G Antigen, Mutant MHC Class Ib Antigen, Mutant MHC Class I Antigen, MHC Class Ib Antigen, MHC Class I Protein, Hla-6.0, MHC-G, HlaG	WB ICC/IF	Human, mouse
	HLA G Antibody (YA9763) is a Rabbit-derived and non-conjugated IgG Monoclonal, Recombinant antibody, targeting to HLA G.

HY-P83098

	HLA-F Antibody (YA2843) HlaF	WB, IHC-P	Human
	HLA-F Antibody (YA2843) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA-F.

HY-P83701

	HLA E Antibody (YA3437) Hla class I histocompatibility antigen E alpha chain antibody; EA1.2 antibody; EA2.1 antibody; Hla 6.2 antibody; Hla class I histocompatibility antigen alpha chain E antibody; Hla class I histocompatibility antigen E alpha chain precursor antibody; Hla class I histocompatibility antigen E alpha chain precursor antibody; Hla6.2 antibody; HlaE antibody; Lymphocyte antigen antibody; Major histocompatibility complex class I E antibody; MHC antibody; MHC class I antigen E antibody; MHC Hla E alpha 1 antibody; MHC Hla E alpha 2.1 antibody; QA1 antibody;	WB, IP, FC	Human
	HLA E Antibody (YA3437) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HLA E.

HY-P82688A

	HLA-DQA1 Antibody (YA2433)(PBS only) Hla-DQA1; CD; CELIAC1; DQ-A1; GSE; Hla-DQA; DQ alpha 1 chain; DC-1 alpha chain; DC-alpha; Hla-DCA; MHC class II DQA1	WB, IHC-P, IP	Human, Mouse, Rat
	HLA-DQA1 Antibody (YA2433) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA-DQA1.

HY-P83274

	HLA-C Antibody (YA3019) MHC; HlaC; HLC-C; D6S204; PSORS1; Hla-JY3	WB, IP	Human, Mouse
	HLA-C Antibody (YA3019) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA-C.

HY-P84044

	HLA-C Antibody (YA3741) MHC; HlaC; HLC-C; D6S204; PSORS1; Hla-JY3	IHC-P, ICC/IF, FC, ELISA	Human
	HLA-C Antibody (YA3741) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HLA-C.

HY-P85015

	HLA-DR Antibody (YA4707) DASS-397D15.1 antibody; DR alpha chain antibody; DR alpha chain precursor antibody; DRA_HUMAN antibody; DRB1 antibody; DRB4 antibody; FLJ51114 antibody; Histocompatibility antigen Hla DR alpha antibody; Histocompatibility antigen Hla-DR alpha antibody; Hla class II histocompatibility antigen antibody; Hla class II histocompatibility antigen DR alpha chain antibody; Hla DR1B antibody; Hla DR3B antibody; Hla DRA antibody; Hla DRA1 antibody; Hla DRB1 antibody; Hla DRB3 antibody; Hla DRB4 antibody; Hla DRB5 antibody; Hla-DR histocompatibility type antibody; Hla-DRA antibody; HlaDR4B antibody; HlaDRA1 antibody; HlaDRB antibody; Major histocompatibility complex class II DR alpha antibody; Major histocompatibility complex class II DR beta 1 antibody; Major histocompatibility complex class II DR beta 3 antibody; Major histocompatibility complex class II DR beta 4 antibody; Major histocompatibility complex class II DR beta 5 antibody; MGC117330 antibody; MHC cell surface glycoprotein antibody; MHC class II antigen DRA antibody; MHC II antibody; MLRW antibody; OTTHUMP00000029406 antibody; OTTHUMP00000029407 antibody; Hla-DRA nanobody;	ELISA	Human
	HLA-DR Antibody (YA4707) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to HLA-DR.

HY-P83915

	HLA-B Antibody (YA3612) AS; HlaB; Bw-47; Bw-50; SPDA1; B-4901; B-5001; Hla-Cw;	WB, IHC-P, ICC/IF, FC, ELISA	Human
	HLA-B Antibody (YA3612) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HLA-B.

HY-P83274A

	HLA-C Antibody (YA3019)(PBS only) MHC; HlaC; HLC-C; D6S204; PSORS1; Hla-JY3	WB, IP	Human, Mouse
	HLA-C Antibody (YA3019) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA-C.

HY-P84044A

	HLA-C Antibody (YA3741)(PBS only) MHC; HlaC; HLC-C; D6S204; PSORS1; Hla-JY3	IHC-P, ICC/IF, FC, ELISA	Human
	HLA-C Antibody (YA3741) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HLA-C.

HY-P83577

	MHC Class I Antibody (YA3322) Aw-68; Hla class I histocompatibility antigen; A-28 alpha chain; MHC class I antigen A68; Hla-A; MHC class I antigen Hla* A heavy chain	WB, IHC-P	Human
	MHC Class I Antibody (YA3322) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MHC Class I.

HY-P81436

	HLA-DPA1 Antibody (YA1181) Hla DPA1; major histocompatibility complex; class II; DP alpha 1; PLT1; HlaDP; HlaSB; DP(W3); DP(W4); Hla-DP1A	IHC-P	Human
	HLA-DPA1 Antibody (YA1181) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA-DPA1.

HY-P83915A

	HLA-B Antibody (YA3612)(PBS only) AS; HlaB; Bw-47; Bw-50; SPDA1; B-4901; B-5001; Hla-Cw;	WB, IHC-P, ICC/IF, FC, ELISA	Human
	HLA-B Antibody (YA3612) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HLA-B.

HY-P84941

	HLA Class 1 ABC Antibody (YA4638) Antigen Presenting Molecule antibody; Cw1701 antibody; D6S204 antibody; FLJ27082 antibody; Hla* A antibody; Hla B antibody; Hla C antibody; Hla class 1 A antibody; Hla class 1 B antibody; Hla class 1 C antibody; Hla JY3 antibody; HlaA antibody; HlaB antibody; HlaC antibody; HLC C antibody; Human Leucocyte Antigen C antibody; Major Histocompatibility Complex Class I A antibody; Major Histocompatibility Complex Class I B antibody; Major Histocompatibility Complex Class I C antibody; Major histocompatibility complex, class I, A + B + C antibody; MHC class I antigen A1 antibody; MHC Class I Antigen antibody; MHC class I antigen B7 antibody; MHC class I antigen Cw1 antibody; MHC class I Hla* A antibody; MHC class I Hla B antibody; MHC class I Hla C antibody; MHC Hla ABC antibody; PSORS1 antibody	ICC/IF, FC	Human
	HLA Class 1 ABC Antibody (YA4638) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HLA Class 1 ABC.

HY-P83577A

	MHC Class I Antibody (YA3322)(PBS only) Aw-68; Hla class I histocompatibility antigen; A-28 alpha chain; MHC class I antigen A68; Hla-A; MHC class I antigen Hla* A heavy chain	WB, IHC-P	Human
	MHC Class I Antibody (YA3322) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MHC Class I.

HY-P81436A

	HLA-DPA1 Antibody (YA1181)(PBS only) Hla DPA1; major histocompatibility complex; class II; DP alpha 1; PLT1; HlaDP; HlaSB; DP(W3); DP(W4); Hla-DP1A	IHC-P	Human
	HLA-DPA1 Antibody (YA1181) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA-DPA1.

HY-P83528

	HLA-DPB1 Antibody (YA3273) Hla class II histocompatibility antigen; DP beta 1 chain; HlaDPB1; HlaDP1B; HlaDM	WB, IHC-P, ICC/IF, IP	Human
	HLA-DPB1 Antibody (YA3273) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA-DPB1.

HY-P83528A

	HLA-DPB1 Antibody (YA3273)(PBS only) Hla class II histocompatibility antigen; DP beta 1 chain; HlaDPB1; HlaDP1B; HlaDM	WB, IHC-P, ICC/IF, IP	Human
	HLA-DPB1 Antibody (YA3273) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA-DPB1.

HY-P87245

	HLA-DRB4 Antibody (YA6933) DR 4 antibody	WB, IHC-P, FC	Human
	HLA-DRB4 Antibody (YA6933) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA-DRB4.

HY-P85199

	HFE Antibody (YA4891) HFE; HlaH; Hereditary hemochromatosis protein; Hla-H	WB, ICC/IF, ELISA	Human
	HFE Antibody (YA4891) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to HFE.

HY-P86901

	HLA DMB Antibody (YA6594) class II antigen Hla-DM beta chain antibody; class II histocompatibility antigen antibody; Class II histocompatibility antigen M beta chain antibody; D6S221E antibody; DMB antibody; Hla class II histocompatibility antigen DM beta chain antibody; Hla-DM histocompatibility type, beta chain antibody; M beta chain antibody; Major histocompatibility complex class II DM beta antibody; MHC class II antigen DMB antibody; class II antigen Hla-DM beta chain antibody; class II histocompatibility antigen antibody; Class II histocompatibility antigen M beta chain antibody; D6S221E antibody; DMB antibody; Hla class II histocompatibility antigen DM beta chain antibody; Hla-DM histocompatibility type, beta chain antibody; M beta chain antibody; Major histocompatibility complex class II DM beta antibody; MHC class II antigen DMB antibody; MHC class II antigen Hla DM beta chain antibody; MHC class II Hla DMB antibody; OTTHUMP00000029257 antibody; Really interesting new gene 7 protein antibody; RING 7 antibody; RING7 antibody;	WB, ICC/IF, IF-Tissue, FC	Human
	HLA DMB Antibody (YA6594) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA DMB.

HY-P81537

	CD74 Antibody (YA1282) CD74; DHlaG; Hla class II histocompatibility antigen gamma chain; Hla-DR antigens-associated invariant chain; Ia antigen-associated invariant chain; Ii; p33; CD74	IHC-P	Human
	CD74 Antibody (YA1282) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD74.

HY-P85007

	CD74 Antibody (YA4699) Hla class II histocompatibility antigen gamma chain; Hla-DR antigens-associated invariant chain; Ia antigen-associated invariant chain; Ii; p33; CD antigen CD74; CD74 nanobody;	ELISA, FC	Human
	CD74 Antibody (YA4699) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CD74.

HY-P81537A

	CD74 Antibody (YA1282)(PBS only) CD74; DHlaG; Hla class II histocompatibility antigen gamma chain; Hla-DR antigens-associated invariant chain; Ia antigen-associated invariant chain; Ii; p33; CD74	IHC-P	Human
	CD74 Antibody (YA1282) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD74.

HY-P85898

	CD74 Antibody (YA5590) CD 74 antibody; CD74 antibody; CD74 antigen; invariant polypeptide of major histocompatibility complex; class II antigen-associated; antibody; CD74 antigen antibody; CD74 molecule antibody; CD74 molecule; major histocompatibility complex; class II invariant chain antibody; CLIP antibody; DHlaG antibody; Gamma chain of class II antigens antibody; HG2A_HUMAN antibody; Hla class II histocompatibility antigen gamma chain antibody; Hla DR antigens associated invariant chain antibody; Hla DR gamma antibody; Hla-DR antigens-associated invariant chain antibody; Hla-DR-gamma antibody; HlaDG antibody; HlaDR antigens associated invariant chain antibody; Ia antigen associated invariant chain antibody; Ia antigen-associated invariant chain antibody; Ia associated invariant chain antibody; Ia gamma antibody; Ii antibody; Invariant polypeptide of major histocompatibility complex class II antigen associated antibody; la-gamma antibody; Major histocompatibility complex class II invariant chain antibody; MHC Hla DR gamma chain antibody; MHC Hla-DR gamma chain antibody; p33 antibody; p35 antibody; Protein 41 antibody;	IHC-P, WB, ICC/IF, ELISA	Human
	CD74 Antibody (YA5590) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CD74.

HY-P81719

	MICA Antibody (YA1464) PERB11.1; MICA; Hla class I antigen antibody; FLJ36918 antibody; FLJ60820 antibody; MGC111087 antibody; MGC21250 antibody; MHC class I chain related gene A protein antibody	WB, IP, FC	Human
	MICA Antibody (YA1464) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MICA.

HY-P83760

	MICA+MICB Antibody (YA3560) Hla class I antigen antibody; FLJ36918 antibody; FLJ60820 antibody; MGC111087 antibody; MGC21250 antibody; MHC class I chain related gene A protein antibody; MIC A antibody; micA antibody; MICA_HUMAN antibody; OTTHUMP00000029088 antibody; PERB11.1 antibody; Stress inducible class I homolog antibody; MHC class I chain related protein B antibody; MICB antibody MICB_HUMAN antibody PERB11.2 antibody Stress inducible class I homolog antibody	WB, IP, FC	Human
	MICA+MICB Antibody (YA3560) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MICA+MICB.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Species:	Human (216) Rhesus Macaque (1) Mouse (5) Cynomolgus (3)
Tag:	SUMO (2) His (222) Avi (205) Myc (1) GST (1) Fc (1)
Source:	HEK293 (211) CHO (1) E. coli (12)

Hla

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products